Latest news

• Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer

  Sales of Xalkori have come under pressure recently as it faces increasing pressure from Roche’s Alecensa (alectinib) and Novartis’ Zykadia (ceritinib), with both therapies having previously bested Pfizer’s ... Although Lorbrena will face extreme

• Roche reports continued growth in Q3, despite biosimilar competition

  In Europe, sales were down 1% thanks to the competition from biosimilars for Herception and Rituxan, but there was growth reported in the uptake of Ocrevus, Perjeta, Tecentriq, Alecensa and Hemlibra.

• Pfizer’s Talzenna cleared for breast cancer in Europe

  Alecensa (alectinib), Novartis’ Zykadia (ceritinib), and Takeda’s Alunbrig (brigatinib).

• Pfizer gets EU nod for Tagrisso rival Vizimpro

  Roche’s Alecensa (alectinib), Novartis’ Zykadia (ceritinib), and Takeda’s Alunbrig (brigatinib).

• Pfizer claims rapid FDA nod for Lorbrena

  Lorbrena can also be used in patients who have seen disease progression on Roche’s Alecensa and Novartis’ Zykadia.